Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

118P - Predictive role of neutrophil lymphocyte ratio (NLR) in metastatic solid tumour patients receiving immune checkpoint inhibitors (ICI)

Date

10 Sep 2022

Session

Poster session 01

Topics

Immunotherapy

Tumour Site

Presenters

Anuradha Mehta

Citation

Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037

Authors

A. Mehta1, S.V. Almel2, M. shaikh3

Author affiliations

  • 1 Medical Oncology Department, P. D. Hinduja National Hospital and Medical Research Centre, 400016 - Mumbai/IN
  • 2 Medical Oncology, P. D. Hinduja National Hospital and Medical Research Centre, 400016 - Mumbai/IN
  • 3 Medical Oncology, Max Institute of Cancer Care, 110024 - New Delhi/IN
More

Abstract 118P

Background

In recent years, neutrophil lymphocyte ratio has been extensively studied as a prognostic marker in patients with solid tumors on the basis that it reflects the inflammatory response to cancer. This study was undertaken to evaluate whether there is any association between clinical benefit rate and progression of disease, using neutrophil lymphocyte ratio as a marker during immunotherapy in advanced solid cancer treatment.

Methods

Sixty adult patients diagnosed with metastatic solid tumors planned to receive ICI were prospectively surveyed. Response evaluation was performed with PET-CT scans after every 4 cycles of ICI or earlier if indicated using RECIST 1.1 criteria. Baseline NLR was correlated with Objective Response Rates (ORR) calculated as the percentage of patients achieving either a complete response (CR) or partial response (PR) and Clinical Benefit Rate (CBR) calculated as the percentage of patients achieving a CR, PR or stable disease (SD) for at least 6 months.

Results

The mean overall duration of treatment of patients with immunotherapy was 119 days. When a baseline NLR value of 5 was used as the cut-off, patients with NLR < 5 (n = 30; 50%) had a significantly longer PFS of 184 days versus 84 days (p< 0.0001). On correlation analysis of baseline NLR with treatment duration, it was found that the Pearson correlation coefficient was -0.369. This shows that baseline NLR was inversely and significantly related to treatment duration, (p value=0.004). The baseline NLR had a sensitivity and specificity of 65% and 54% respectively in predicting progression. Low NLR had significant correlation with achieving a SD or a PR, that is achieving a CBR (p = 0.001). Amongst the 37 patients with negative ORR, 60% patients had high NLR. 85% of the patients with positive ORR had low NLR (p value=0.009). Out of the 39 patients receiving clinical benefit from the immunotherapy, 26 patients had low NLR (66.67%) (p value<0.0001).

Conclusions

An NLR of less than or equal to 4.5 was found to be useful in predicting CBR. The baseline NLR was inversely and significantly related to treatment duration and hence the progression of disease. Therefore NLR has the potential to be readily available as a prognostic indicator for patients receiving ICI.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.